Lipid lowering drug and other toxic myopathies

被引:7
|
作者
Schoser, BGH [1 ]
Pongratz, D [1 ]
机构
[1] Univ Munich, Neurol Klin, Friedrich Baur Inst, D-80336 Munich, Germany
来源
INTERNIST | 2005年 / 46卷 / 11期
关键词
myopathy; toxic myopathy; lipid lowering drug myopathy; rhabdomyolysis;
D O I
10.1007/s00108-005-1490-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A growing number of therapeutic agents and exogenous toxins are harmful to structure and function of human skeletal muscle. The clinical syndrome encompasses asymptomatic creatine kinase elevation, myalgia, exercise intolerance, muscle paresis and atrophy, and lastly acute rhabdomyolysis. Toxic myopathies are potentially reversible, hence a prompt recognition is particularly helpful for the early diagnosis and in conclusion elimination of a myopathy inducing toxin. Toxic myopathies may be classified as acute or chronic accordingly to the exposition time to a toxin. Main source of an exogenous induced toxic myopathy is chronic alcohol abuse. Alcohol excess induces acute and/or chronic neuropathy and myopathy, consequently muscle wasting and weakness occurs. Drug-induced myopathies are most frequently seen due to amplified utilization of corticosteroids or lipid lowering agents.
引用
收藏
页码:1198 / +
页数:7
相关论文
共 50 条
  • [1] Lipidsenker- und andere toxische MyopathienLipid lowering drug and other toxic myopathies
    B. G. H. Schoser
    D. Pongratz
    Der Internist, 2005, 46 : 1198 - 1206
  • [2] Zebrafish as a Model for the Study of Lipid-Lowering Drug-Induced Myopathies
    Dubinska-Magiera, Magda
    Migocka-Patrzalek, Marta
    Lewandowski, Damian
    Daczewska, Malgorzata
    Jagla, Krzysztof
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (11)
  • [3] Genetic risk factors associated with lipid-lowering drug-induced myopathies
    Vladutiu, Georgirene D.
    Simmons, Zachary
    Isackson, Paul J.
    Tarnopolsky, Mark
    Peltier, Wendy L.
    Barboi, Alexandru C.
    Sripathi, Naganand
    Wortmann, Robert L.
    Phillips, Paul S.
    MUSCLE & NERVE, 2006, 34 (02) : 153 - 162
  • [4] Drug-induced and toxic myopathies
    Guis, S
    Mattéi, JP
    Lioté, F
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2003, 17 (06): : 877 - 907
  • [5] Toxic and drug-induced myopathies
    Dalakas, M. C.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (08): : 832 - 838
  • [6] Myopathies under therapy with lipid-lowering agents
    Köller, H
    Neuhaus, O
    Schroeter, M
    Hartung, H
    NERVENARZT, 2005, 76 (02): : 212 - 217
  • [7] Drug interactions in cardiology: focus on statins and their combination with other lipid-lowering drugs
    Bellosta, Stefano
    Corsini, Alberto
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (11-12) : 1013 - 1021
  • [8] Toxic Myopathies
    Pasnoor, Mamatha
    Barohn, Richard J.
    Dimachkie, Mazen M.
    NEUROLOGIC CLINICS, 2014, 32 (03) : 647 - +
  • [9] Drug interactions with lipid lowering drugs
    Becquemont, L
    THERAPIE, 2003, 58 (01): : 85 - 90
  • [10] Toxic Myopathies
    Schneider, Ilka
    Kendzierski, Thomas
    Zierz, Stephan
    KLINISCHE NEUROPHYSIOLOGIE, 2022, 53 (01) : 29 - 35